The U.S. Food and Drug Administration (FDA) has just approved Blujepa (gepotidacin) – the first in a new class of oral antibiotics for uncomplicated urinary tract infection (uUTI) in nearly 30 years based on the results of a clinical study conducted at the following Frontier Clinical Research sites: Kingwood, WV; Morgantown (Waterfront), WV; Scottdale, PA; and Smithfield, PA.
Frontier Clinical Research’s dedicated participation was essential in helping GSK present data to the FDA establishing a favorable benefit of gepotidacin in adult and pediatric patients aged 12 and older with uUTI and has also more broadly helped advance medical and scientific knowledge.
Thank you very much to our staff and participants of this study.
Read more: https://www.cnn.com/2025/03/25/health/uti-antibiotic-fda-gepotidacin-blujepa/index.html
